AU2022274249A1 — 6-hydroxy-cannabidiol-c4
Assigned to Jazz Pharmaceuticals Research UK Ltd · Expires 2023-11-09 · 3y expired
What this patent protects
The present invention relates to a compound that is pharmaceutically active and methods of preparation thereof. The compound of the invention is 6-hydroxy-cannabidol-C4 (6-OH- CBD-C4). The compound of the invention is related to cannabidiol (CBD). CBD is a non- psychoactive canna…
USPTO Abstract
The present invention relates to a compound that is pharmaceutically active and methods of preparation thereof. The compound of the invention is 6-hydroxy-cannabidol-C4 (6-OH- CBD-C4). The compound of the invention is related to cannabidiol (CBD). CBD is a non- psychoactive cannabinoid which has been used to treat various diseases and disorders. While such treatments hold promise, there remains a need in the art for more effective treatments and this has been brought about by way of the compound of the invention.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.